ExLibris header image
SFX Logo
Title: Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth
Source:

Gene Therapy [0969-7128] yr:2019


Collapse list of basic services Basic
Full text
Full text available via Nature
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. "Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer." Pharmacological research. 164: 105305-105305. Link to SFX for this item
2. Kurhanewicz, J. "Hyperpolarized 1-[ 13 C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer." European urology 72.6 (2017): 1028-1029. Link to SFX for this item
3. Anderson, Mark A. "Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography." British journal of radiology 94.1118 (2021): 20200663-20200663. Link to Full Text for this item Link to SFX for this item
4. "The role of immune checkpoint inhibitors in prostate cancer." Annals of the agricultural and environmental medicine 26.1: 120-124. Link to SFX for this item
5. Morris, Robert H. "Transient effect determination of spin-lattice (TEDSpiL) relaxation times using continuous wave NMR." Magnetic resonance in chemistry 55.9 (2017): 853-855. Link to Full Text for this item Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.